Nasonex Nasal Spray: Expert Relief for Allergic Rhinitis Symptoms
Nasonex nasal spray
| Product dosage: 18g | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 2 | $31.00 | $62.00 (0%) | 🛒 Add to cart |
| 3 | $30.00 | $93.00 $90.00 (3%) | 🛒 Add to cart |
| 4 | $29.25 | $124.00 $117.00 (6%) | 🛒 Add to cart |
| 5 | $28.60 | $155.00 $143.00 (8%) | 🛒 Add to cart |
| 6 | $28.33 | $186.00 $170.00 (9%) | 🛒 Add to cart |
| 7 | $28.00 | $217.00 $196.00 (10%) | 🛒 Add to cart |
| 8 | $27.88 | $248.00 $223.00 (10%) | 🛒 Add to cart |
| 9 | $27.78 | $279.00 $250.00 (10%) | 🛒 Add to cart |
| 10 | $27.60
Best per sprayer | $310.00 $276.00 (11%) | 🛒 Add to cart |
Synonyms | |||
Nasonex Nasal Spray (mometasone furoate monohydrate) is a prescription corticosteroid nasal spray developed for the management of seasonal and perennial allergic rhinitis symptoms in adults and pediatric patients. Manufactured by Organon & Co., this intranasal formulation delivers targeted anti-inflammatory action directly to nasal passages, reducing mucosal inflammation, congestion, sneezing, and rhinorrhea. Its once-daily dosing regimen supports adherence while its safety profile makes it suitable for long-term use under medical supervision. Clinically proven and widely prescribed, Nasonex represents a cornerstone in allergic rhinitis management protocols.
Features
- Active ingredient: mometasone furoate monohydrate equivalent to 50 mcg mometasone furoate per spray
- Delivery system: metered-dose, manual pump spray bottle
- Presentation: 60 or 120 actuations per container
- pH-balanced aqueous suspension
- Benzalkonium chloride preserved formulation
- Alcohol-free and non-sedating
- Suitable for patients aged 2 years and older
Benefits
- Provides significant reduction in nasal congestion, sneezing, and runny nose within 24-48 hours of initiation
- Offers sustained 24-hour symptom control with once-daily dosing
- Minimizes systemic absorption due to low bioavailability (<0.1%)
- Reduces nasal inflammation at the cellular level by inhibiting cytokine production
- Improves quality of life measures including sleep quality and daytime functioning
- Prevents recurrence of nasal polyps following surgical removal
Common use
Nasonex Nasal Spray is primarily indicated for the treatment of seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis in adults and children ages 2 years and older. It is also approved for the prophylaxis of seasonal allergic rhinitis symptoms when initiated 2-4 weeks prior to anticipated pollen exposure. Additionally, Nasonex is indicated for the treatment of nasal polyps in patients 18 years of age and older, particularly for reducing polyp size and improving nasal airflow. Off-label uses include adjunctive treatment of acute rhinosinusitis and eosinophilic nonallergic rhinitis, though these applications require physician supervision.
Dosage and direction
For allergic rhinitis in adults and adolescents 12 years and older: 2 sprays (100 mcg) in each nostril once daily (total daily dose 200 mcg). For seasonal allergic rhinitis prophylaxis: begin 2-4 weeks before anticipated pollen season. For children 2-11 years: 1 spray (50 mcg) in each nostril once daily (total daily dose 100 mcg). For nasal polyps in adults: 2 sprays (100 mcg) in each nostril twice daily (total daily dose 400 mcg); may reduce to once daily after symptom improvement.
Administration technique: Shake bottle gently before use. Prime pump by actuating 10 times until fine spray appears. Insert tip into nostril, pointing slightly toward the outer corner of the eye. Breathe in gently through nose while spraying. Avoid spraying directly toward nasal septum. Clean applicator regularly with warm water.
Precautions
Patients should inform their physician if they experience recent nasal septum ulcers, nasal surgery, or nasal trauma. Use with caution in patients with tuberculosis, untreated fungal, bacterial, or viral systemic infections, or ocular herpes simplex. Monitor patients switching from systemic corticosteroids to Nasonex for adrenal insufficiency. Nasal corticosteroids may cause slowed growth in children; regularly monitor pediatric patients’ growth patterns. Avoid exposure to chickenpox or measles if no previous immunity exists. Patients with glaucoma or elevated intraocular pressure should be monitored regularly.
Contraindications
Hypersensitivity to mometasone furoate or any component of the formulation. Not recommended for the treatment of nonallergic rhinitis. Contraindicated in patients with active or quiescent tuberculosis infections of the respiratory tract. Should not be used for emergency treatment of acute asthma episodes or other acute bronchospasm. Avoid use in patients with untreated localized infections involving the nasal mucosa.
Possible side effects
Common side effects (≥3%): headache (8%), viral infection (4%), pharyngitis (6%), epistaxis (8%), nasal burning/irritation (5%). Less common side effects: nasal ulceration, candidiasis, blurred vision, cough, musculoskeletal pain. Rare but serious effects: nasal septum perforation, increased intraocular pressure, glaucoma, cataracts, adrenal suppression, hypersensitivity reactions including anaphylaxis. Children may experience more frequent reports of epistaxis than adults.
Drug interaction
Although systemic absorption is minimal, potential interactions exist with strong CYP3A4 inhibitors (ketoconazole, ritonavir) which may increase mometasone plasma concentrations. No clinically significant interactions identified with commonly co-administered allergic rhinitis medications including antihistamines or decongestants. Theoretical potential for additive immunosuppression when used with other immunosuppressive agents.
Missed dose
If a dose is missed, administer as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Maintain regular dosing schedule; consistency is important for optimal therapeutic effect. If multiple doses are missed, symptoms may return; contact healthcare provider if symptom breakthrough occurs.
Overdose
Acute overdose is unlikely due to limited systemic absorption. Single doses up to 20 times the recommended dose have been administered without adverse effects. Chronic excessive use may lead to systemic corticosteroid effects including hypercorticism and adrenal suppression. Treatment should be symptomatic and supportive. There is no specific antidote. Consider monitoring adrenal function in cases of chronic overdose.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Do not freeze. Keep bottle upright and protected from light. Discard after 120 actuations (or as marked on packaging) even if bottle is not completely empty. Keep out of reach of children. Do not store in bathroom where moisture could affect drug stability. Do not puncture or incinerate container.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Nasonex Nasal Spray is available by prescription only. Always consult with a qualified healthcare professional before starting, stopping, or changing any medication regimen. Individual results may vary. Full prescribing information is available from the manufacturer or your healthcare provider.
Reviews
Clinical studies demonstrate Nasonex’s efficacy with 70-80% of patients experiencing significant symptom improvement within 1-2 days of treatment. In comparative trials, Nasonex showed superior congestion relief versus placebo and non-inferiority to other intranasal corticosteroids. Patient satisfaction surveys indicate high rates of continued use due to effectiveness and convenience of once-daily dosing. Healthcare providers consistently rate Nasonex as a first-line option for allergic rhinitis management based on its favorable efficacy-to-safety profile.